Gaithersburg, Maryland – March 14, 2019: MaxCyte announced today that Doug Doerfler, Chief Executive Officer, will provide a company overview at the Alliance for Regenerative Medicine’s (ARM) 7th Annual Cell & Gene Therapy Investor Day, on Thursday, March 21 at 11:40 a.m. in New York City.
For more information about the conference, please visit: www.arminvestorday.com.
MaxCyte is a clinical-stage global cell-based medicines and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA™ therapies for its own pipeline, with its first drug candidate in a Phase 1 clinical trial. CARMA is MaxCyte’s mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its core business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 70 partnered program licenses in cell therapy including more than 35 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com
For further information, please contact:
|Doug Doerfler, Chief Executive Officer|
|+1 301 944 1660|
|US Investor Relations|
US Media Relations
+1 410 299 3310
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter